New Criteria for Diagnosing and Staging Alzheimer’s Disease Released by Alzheimer’s Association Task Force

A task force convened by the Alzheimer’s Association has released new criteria aimed at improving clinical research and assisting clinicians in evaluating cognitive impairment. The revised criteria for diagnosing and staging Alzheimer’s disease shift the focus from symptom observation to detecting the underlying biological processes of neurodegenerative diseases. This new approach aligns with the 2018 research framework by the National Institute on Aging and the Alzheimer’s Association (NIA-AA). Inaccurate diagnoses of cognitive syndromes, including mild cognitive impairment or dementia, have been common, but recent advancements in therapies, like amyloid-targeting monoclonal antibodies (lecanemab and donanemab), underscore the need for precise diagnosis in the management of Alzheimer’s disease.¹

Read more here.

References

1. Editorial, Brookes, A., Connect Images, & Science Photo Library. (2024). The evolving paradigm of Alzheimer’s disease diagnosis. In The Lancet Neurology (Vol. 23, p. 845) [Journal-article]. https://www.thelancet.com/action/showPdf?pii=S1474-4422%2824%2900329-6

Disclaimers

• The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
• Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
• No official support by any organization(s) has been provided or should be inferred

Recommended Reads

• EMA news: Establishing efficacy based on single-arm trials in marketing authorisations
• India’s ascendancy in 2023
• EMA recommends first vaccine to protect older adults from RSV
• Is There a Benefit to the Covid-19 Pandemic?
• COVID-19 Vaccine Development and Testing at a Record-Setting Rate